An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients With Advanced Solid Tumors
European Journal of Drug Metabolism and Pharmacokinetics - France
doi 10.1007/s13318-020-00607-7
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 18, 2020
Authors
Publisher
Springer Science and Business Media LLC